CliffBio
small molecule

BIAXIN

CLARITHROMYCIN

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameBIAXIN
Active ingredientCLARITHROMYCIN
Strength250MG/5ML
Dosage formFOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalDecember 1993
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

BIAXIN patent cliff — loss of exclusivity — | CliffBio